Cargando…
Interleukin-24 enhancing antitumor activity of chimeric oncolytic adenovirus for treating acute promyelocytic leukemia cell
BACKGROUND: Acute promyelocytic leukaemia (APL) is a clonal disease arising by hematopoietic stem cell (HSC), which characterized by inappropriate proliferation/differentiation or survival of immature myeloid progenitors. Oncolytic adenoviruses have been under widespread investigation as anticancer...
Autores principales: | , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Wolters Kluwer Health
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6708966/ https://www.ncbi.nlm.nih.gov/pubmed/31145345 http://dx.doi.org/10.1097/MD.0000000000015875 |
_version_ | 1783446099093094400 |
---|---|
author | Liu, Li Ma, Jiabin Qin, Lanyi Shi, Xiaogang Si, Hongqiang Wei, Yahui |
author_facet | Liu, Li Ma, Jiabin Qin, Lanyi Shi, Xiaogang Si, Hongqiang Wei, Yahui |
author_sort | Liu, Li |
collection | PubMed |
description | BACKGROUND: Acute promyelocytic leukaemia (APL) is a clonal disease arising by hematopoietic stem cell (HSC), which characterized by inappropriate proliferation/differentiation or survival of immature myeloid progenitors. Oncolytic adenoviruses have been under widespread investigation as anticancer agents. Recently, our data suggested that tumor cells were cured by AdCN205-IL-24, an adenovirus serotype 5-based conditionally replicating adenovirus expressing IL-24 after infection. METHODS: In this study, we created a novel fiber chimeric oncolytic adenovirus AdCN306-IL-24 that has Ad11 tropism and approved CAR (coxsackie adenovirus receptor, CAR)-independent cell entry, which could allow development of selective cytopathic effects (CPE) in APL cells in vitro. RESULTS: Formidable cytotoxic effect was specifically implemented in APL cells after infection with AdCN306-IL-24. The expression of IL-24 was up-regulated upon treated with accepted tumors. And the vector also induced superior cytolytic effects activity in APL cells by activation of programmed cell death. CONCLUSIONS: Taken together, our data suggested that chimeric oncolytic adenovirus AdCN306-IL-24 could express IL-24 gene, representing a potential therapeutics for acute promyelocytic leukemia. |
format | Online Article Text |
id | pubmed-6708966 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2019 |
publisher | Wolters Kluwer Health |
record_format | MEDLINE/PubMed |
spelling | pubmed-67089662019-10-01 Interleukin-24 enhancing antitumor activity of chimeric oncolytic adenovirus for treating acute promyelocytic leukemia cell Liu, Li Ma, Jiabin Qin, Lanyi Shi, Xiaogang Si, Hongqiang Wei, Yahui Medicine (Baltimore) Research Article BACKGROUND: Acute promyelocytic leukaemia (APL) is a clonal disease arising by hematopoietic stem cell (HSC), which characterized by inappropriate proliferation/differentiation or survival of immature myeloid progenitors. Oncolytic adenoviruses have been under widespread investigation as anticancer agents. Recently, our data suggested that tumor cells were cured by AdCN205-IL-24, an adenovirus serotype 5-based conditionally replicating adenovirus expressing IL-24 after infection. METHODS: In this study, we created a novel fiber chimeric oncolytic adenovirus AdCN306-IL-24 that has Ad11 tropism and approved CAR (coxsackie adenovirus receptor, CAR)-independent cell entry, which could allow development of selective cytopathic effects (CPE) in APL cells in vitro. RESULTS: Formidable cytotoxic effect was specifically implemented in APL cells after infection with AdCN306-IL-24. The expression of IL-24 was up-regulated upon treated with accepted tumors. And the vector also induced superior cytolytic effects activity in APL cells by activation of programmed cell death. CONCLUSIONS: Taken together, our data suggested that chimeric oncolytic adenovirus AdCN306-IL-24 could express IL-24 gene, representing a potential therapeutics for acute promyelocytic leukemia. Wolters Kluwer Health 2019-05-31 /pmc/articles/PMC6708966/ /pubmed/31145345 http://dx.doi.org/10.1097/MD.0000000000015875 Text en Copyright © 2019 the Author(s). Published by Wolters Kluwer Health, Inc. http://creativecommons.org/licenses/by/4.0 This is an open access article distributed under the Creative Commons Attribution License 4.0 (CCBY), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. http://creativecommons.org/licenses/by/4.0 |
spellingShingle | Research Article Liu, Li Ma, Jiabin Qin, Lanyi Shi, Xiaogang Si, Hongqiang Wei, Yahui Interleukin-24 enhancing antitumor activity of chimeric oncolytic adenovirus for treating acute promyelocytic leukemia cell |
title | Interleukin-24 enhancing antitumor activity of chimeric oncolytic adenovirus for treating acute promyelocytic leukemia cell |
title_full | Interleukin-24 enhancing antitumor activity of chimeric oncolytic adenovirus for treating acute promyelocytic leukemia cell |
title_fullStr | Interleukin-24 enhancing antitumor activity of chimeric oncolytic adenovirus for treating acute promyelocytic leukemia cell |
title_full_unstemmed | Interleukin-24 enhancing antitumor activity of chimeric oncolytic adenovirus for treating acute promyelocytic leukemia cell |
title_short | Interleukin-24 enhancing antitumor activity of chimeric oncolytic adenovirus for treating acute promyelocytic leukemia cell |
title_sort | interleukin-24 enhancing antitumor activity of chimeric oncolytic adenovirus for treating acute promyelocytic leukemia cell |
topic | Research Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6708966/ https://www.ncbi.nlm.nih.gov/pubmed/31145345 http://dx.doi.org/10.1097/MD.0000000000015875 |
work_keys_str_mv | AT liuli interleukin24enhancingantitumoractivityofchimericoncolyticadenovirusfortreatingacutepromyelocyticleukemiacell AT majiabin interleukin24enhancingantitumoractivityofchimericoncolyticadenovirusfortreatingacutepromyelocyticleukemiacell AT qinlanyi interleukin24enhancingantitumoractivityofchimericoncolyticadenovirusfortreatingacutepromyelocyticleukemiacell AT shixiaogang interleukin24enhancingantitumoractivityofchimericoncolyticadenovirusfortreatingacutepromyelocyticleukemiacell AT sihongqiang interleukin24enhancingantitumoractivityofchimericoncolyticadenovirusfortreatingacutepromyelocyticleukemiacell AT weiyahui interleukin24enhancingantitumoractivityofchimericoncolyticadenovirusfortreatingacutepromyelocyticleukemiacell |